Eton Pharmaceuticals (Eton Pharmaceuticals) Ending Cash Position : $16.66 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals Ending Cash Position?

Eton Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 was $16.66 Mil.

Eton Pharmaceuticals's quarterly Ending Cash Position declined from Sep. 2023 ($22.07 Mil) to Dec. 2023 ($21.39 Mil) and declined from Dec. 2023 ($21.39 Mil) to Mar. 2024 ($16.66 Mil).

Eton Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 ($14.41 Mil) to Dec. 2022 ($16.31 Mil) and increased from Dec. 2022 ($16.31 Mil) to Dec. 2023 ($21.39 Mil).

Eton Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Eton Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals Ending Cash Position Chart

Eton Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

12.07

21.30

14.41

16.31

21.39

Eton Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															14.71	21.57	22.07	21.39	16.66

Eton Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Eton Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	16.305	+	5.083
	=	21.39

Eton Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	21.388	+	-4.733
	=	16.66

Eton Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278

Website

https://www.etonpharma.com

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.

Executives

David Krempa	officer: Chief Business Officer	29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen	director, officer: President & CEO	C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber	officer: Chief Financial Officer	618 AMES STREET, LIBERTYVILLE IL 60048
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
William Wilson Troutman	officer: CFO, Treasurer & Secretary	21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc.	10 percent owner	102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams	director	5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum	director	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121